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Background. Although subSaharan Africa faces the world’s largest paediatric HIV epidemic, only 1 in 4 children has access to 
combination antiretroviral therapy (ART). A decentralised approach to HIV care is advocated, but programmes in resource-
limited settings encounter many challenges to community-initiated paediatric ART implementation. 
Methods. A retrospective cohort analysis of 613 children receiving ART between 2004 and 2009 was performed in seven 
physician-run primary healthcare (PHC) clinics in Cape Town. Baseline characteristics, serial CD4+, viral load (VL) levels and 
status at study closure were collected. 
Results. Two subgroups were identified: children who were initiated on ART in a PHC clinic (n=343) and children who were 
down-referred from tertiary hospitals (n=270). The numbers of children initiated on ART in PHC increased sevenfold over the 
study period. Down-referred children were severely ill at ART initiation, with higher VLs, lower CD4+ counts and higher rates of 
tuberculosis co-infection (25.3% v. 16.9%; p=0.01). Median time to virological suppression was 29 weeks in PHC-ART initiates 
and 44 weeks in children down-referred (p<0.0001). Children down-referred to PHC either maintained or gained virological 
suppression. Longitudinal cohort analysis demonstrated sustained VL suppression >80%, high rates of immune reconstitution 
and low mortality.
Conclusions. Increasing numbers of children are initiated on ART in PHC settings and achieve comparable immunological, 
virological and survival outcomes, suggesting successful decentralisation of paediatric HIV care. Down-referral of children 
with adherence-related virological failure may assist with attainment of virological suppression and sparing use of second-line 
medications.
S Afr J HIV Med 2014;15(4):148-153. DOI:10.7196/SAJHIVMED.1084
The World Health Organization (WHO) estimates 
that of the 2.5 million children living with HIV, 
90% reside in subSaharan Africa.[1] South Africa 
(SA) faces the world’s largest HIV epidemic, with 
a staggering 330 000 children affected. Perinatally 
acquired HIV infection is associated with high mortality. Without 
intervention, approximately half of all HIV-infected children will 
die by their second birthday[2-4] and 35% of SA children who die 
before their 5th birthday fall victim to an AIDS-related disease. [5] 
More recent pooled data from southern African paediatric HIV 
programmes reported persistently high mortality in infants 
(46.3%) despite large-scale ART roll-out.[6] 
Combination antiretroviral therapy (ART) is the only effective 
treatment available for the suppression of HIV, and early ART 
initiation significantly reduces AIDS-related morbidity and 
mortality.[7,8] Children in developed countries receive ART 
as the standard of care upon initial diagnosis; however, it is 
estimated that only 1 in 4 children living in subSaharan Africa 
receives this life-sustaining treatment.[1] Barriers to paediatric 
treatment abound in subSaharan Africa: delayed diagnosis due 
to lack of capacity for HIV DNA polymerase chain reaction 
(PCR) testing, inadequate number of clinicians and staff 
trained to provide paediatric HIV management, and scarcity of 
paediatric ART drug formulations, among others. [9-11] 
The WHO has recommended a decentralised, public health-
centred approach for HIV care in resource-limited settings since 
2000.[12,13] Owing to the high level of human resources and logistical 
coordination needed to maintain a paediatric clinical practice and 
pharmacy, paediatric ART programmes have historically been 
located at tertiary centres and research units. With a large rural-
based population in SA, access to urban ART treatment facilities is 
associated with significant direct and indirect costs.
In the Western Cape Province of SA, paediatric ART first 
became available to public sector patients in 2004. With expansion 
of diagnostic and paediatric HIV management capacity, a 
decentralised approach to ART delivery was achieved in Cape 
Town’s Eastern Metropole. Government and the President’s 
Emergency Plan For AIDS Relief (PEPFAR)-funded paediatric 
clinicians (from the Infectious Disease Clinic (IDC) at Tygerberg 
Children’s Hospital (TBH)) provided support to seven primary 
healthcare (PHC) outreach sites: Ikwezi, Grabouw, Kraaifontein, 
and Delft clinics; and Eerste River, Helderberg and Karl Bremer 
hospitals. Between 2004 and 2006, this decentralised approach to 
care resulted in a decrease in the number of Cape Town children 
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receiving ART at tertiary centres (Red Cross War 
Memorial Children’s Hospital, Groote Schuur 
Hospital and TBH) from 78.4% to 38%.[11] 
As evidence mounts for successful initiation 
of paediatric ART care in rural and urban 
community-based PHC clinics,[13-18] the need 
to evaluate paediatric down-referral outcomes 
remains. A systematic review of decentralised 
HIV care (including three studies with paediatric 
data) demonstrated comparable outcomes, with 
similar or reduced patient attrition and death at 
12 months.[19] Two large studies in sub Saharan 
Africa demonstrated lower mortality and default 
rates among down-referred patients; it is notable, 
however, that the option of down-referral was 
only offered to stable, compliant patients on first-
line ART.[20,21] A unique cohort of children has 
developed within the PHC network, as clinician-
driven longitudinal care was provided for both 
ART-naive initiates and those down-referred 
from tertiary facilities. Characterisation of this 
retrospective cohort not only provides evidence 
of the favourable long-term immunological and 
virological outcomes of PHC-managed children, 
but unique insight into the characteristics and 
outcomes of children who cross health-system 
strata through a down-referral process to 
community-based HIV care.
Methods
Children under 14 years of age (who were either 
newly initiated on ART or down-referred for 
continued ART management between 1 January 
2004 and 30 January 2009) were identified for 
study inclusion from the PHC clinic registers 
at seven TBH-supported, community-based 
paediatric ART clinics. Retrospective cohort 
data were obtained from the IDC database (an 
electronic register of clinical and outcome data 
for children at the seven outreach clinics) to 
create a novel database including date of birth, 
first visit date at an HIV clinic, ART initiation 
date, ART initiation site, baseline WHO clinical 
stage, 6-monthly CD4+ count and viral loads 
(VLs). Dates of tuberculosis (TB) treatment, 
loss to follow-up and deaths were also extracted. 
Missing data were retrieved from the National 
Health Laboratory Service (NHLS) server or 
through clinic-based record reviews. Patients 
identified without follow-up data (as a result 
of ART discontinuation, transfer in or transfer 
out, death or loss to follow-up within 6 months 
of arrival in the PHC network) were categorised 
as ‘baseline’; those with at least 6 months of 
follow-up data within the PHC network were 
assigned to the ‘longitudinal’ cohort. 
Serial CD4+ counts and HIV VLs were 
ordered by physicians at 6-month intervals 
as part of standard HIV-care protocols in 
the Western Cape. Available laboratory data 
(within 3 months of each 6-monthly visit 
postART initiation) were included in the 
database. All laboratory testing was performed 
by the NHLS with public funds. Within the 
NHLS lab, CD4+ percentages are measured 
through the application of a dual-platform, 
dual-colour PanLeucogating CD45-assisted 
flow cytometry machine.[22] VLs were initially 
measured using the NucliSens HIV-1 QT assay 
(bio-Merieux, Boxtel, The Netherlands), which 
yielded VLs undetectable below 400 copies/mL. 
Advances in sensitivity with the introduction of 
the NucliSens EasyQ HIV-q assay allowed more 
precise quantification of low-level viraemia; 
however, all VL values less than 400 copies/mL 
were treated as ‘suppressed’.
Clinically significant virological failure 
(VF) was defined as two sequential VL values 
>1 000 copies/mL. Once patients with VF 
were identified, paediatric clinicians were 
asked to provide a clinical vignette describing 
adherence issues or the presumed underlying 
cause for VF. Maximal mortality was defined 
as documented deaths in addition to those lost 
to follow-up (LTFU). Survival analyses were 
calculated using the time to actual event or 
date of last evaluation.
The research ethics committees at Stellen-
bosch University and the University of Cape 
Town provided approval of this project. 
Additionally, permission to access patient 
health information was granted by the Deputy-
Director General of District Health Services and 
Programmes within the Provincial Government 
of the Western Cape’s Department of Health. 
Statistical analysis
Data were compiled into Excel spreadsheets 
and uploaded to Stata Statistical Software 
version 10.0 (StataCorp LP, USA) for analysis. 
Continuous variables were stratified by both 
ART initiation site (PHC v. down-referred) 
and longevity within the PHC network 
(baseline v. longitudinal) and explored 
for normalcy; all values were accordingly 
analysed with non-parametric Wilcoxon 
sum rank test for subcohort comparisons. 
Categorical frequencies were also stratified 
by ART initiation site and duration of care 
within the PHC network. A two-sample test 
of proportion was utilised to detect differences 
between subgroup frequencies.
Kaplan-Meier survival analysis was performed 
to identify median time to VL suppression 
with stratification with categorical variables 
hypothesised to influence time to suppression. 
Multiple logistic regression was performed to 
explore variables (including protease inhibitor-
containing ART and TB co-infection) that 
may be related to the risk of developing VF.[23] 
No variables were identified as having a 
confounding and effect-modifiying influence; 
however, baseline WHO clinical classification 
was so significantly predictive of VF that the 
variable was restricted from the model because 
of colinearity. Manual and automated model 
building were performed to create a best-fit 
model, which ultimately included ART initiation 
site and baseline VL log. Model diagnostics 
identified one patient who was a very significant 
influential outlier. As this patient had laboratory 
and clinical findings consistent with that of a 
long-term non-progressor, he was eliminated 
from the final model.
Results
Cohort characteristics
A total of 848 patients were identified within the 
seven PHC ART clinics, of whom 613 (72.3%) 
met our inclusion criteria. Two unique cohorts 
ART initiation in
PHC (n=343)
Down-referred on
ART (n=270)
PHC ART cohort (n=613)
Baseline data
(n=182)
Longitudinal data
(n=431)
Ineligible PHC patients (n=235)
153 (65%) = HIV-infected, not on ART
68 (29%) = dates of care in PHC not
eligible by inclusion criteria
7 (3%) = signicant missing data
5 (2%) = PHC not medical home
2 (1%) = HIV-exposed, uninfected
Fig. 1. Study profile. (ART = antiretroviral therapy; PHC = primary healthcare.)
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existed within the PHC network: those who 
were initiated on ART at higher levels of care 
and were down-referred to PHC, and those who 
were initiated on ART in PHC. The majority of 
those ineligible for analysis were HIV-infected 
patients who had not been initiated on ART 
before the end of our study period (Fig. 1).  
Table 1 lists ART cohort characteristics 
stratified by ART initiation site. Baseline 
illness severity at the time of ART initiation, as 
measured by WHO clinical categorisation, was 
significantly different between initiation sites; 
proportionally more severely ill children started 
ART at higher levels of care than at PHC clinics 
(p<0.0001). Additionally, those who were down-
referred had significantly lower baseline CD4+ 
percentages (p=0.01), higher VLs (p=0.0004) 
and greater likelihood of TB co-infection at the 
time ART was initiated (p=0.01). 
Similar trends in increased clinical severity 
(p<0.0001), higher baseline VL (p=0.01) and 
greater proportions of asymptomatic infants 
initiated on ART exist among those whose data 
were available for longitudinal analysis. Owing 
to the intensified ART roll-out in the latter half 
of the study period, the baseline cohort had a 
larger proportion of PHC-initiated patients, 
while the longitudinal cohort was skewed 
towards those down-referred (p<0.0001) 
(Fig. 2). The characteristics and demographics 
of the baseline data group were therefore largely 
reflective of a recently initiated, lower-acuity 
group who initiated ART in PHC. Conversely, 
children in the longitudinal group were more 
likely to be severely ill at the time of ART 
initiation, and by definition had been ART-
exposed for a longer period of time.
Overall, the majority of children prescribed 
ART had laboratory evidence of advanced 
or severe immunosuppression. Those 
without immunosuppression, however, were 
significantly more likely to have initiated ART 
outside of the PHC system (p=0.017). Sub-
analysis confirmed increasing implementation 
of the revised WHO recommendations (based 
on the CHER trial results),[24] which recommend 
ART initiation in infancy (p=0.026). 
Virological outcomes
The median duration of follow-up was 
28 months (interquartile range (IQR) 16.5 - 42.6) 
Table 1. PHC ART cohort characteristics stratified by ART initiation site
Variable
Total PHC cohort 
(N=613)
ART initiation in PHC 
(n=343)
Down-referred on ART 
(n=270) p-value
Gender (male) (%) 46 48 44 0.358   
Age at ART start (months), median (IQR) 26.4
(10.2 - 63)
29.6
(10.0 - 68.4)
25.1
(10.5 - 59.3) 0.386
WHO clinical stage (%)
I 7.0 10.0 2.9 0.0009
II 14.2 19.2 7.4 0.0001
III/IV (severe) 78.9 70.7 89.8 <0.0001
Baseline CD4+ (cells/µL), median (IQR) 619 (323 - 1 119) 608 (313 - 1 151) 650 (340 - 1 051) 0.879 
Baseline CD4+ percentage, median (IQR) 16.7 (10.7 - 23.3) 17.8 (11.0 - 24.2) 16 (10.0 - 21.8) 0.016
Immunological category (%)
No IS 22.5 19.0 27.0 0.017
Mild IS 18.0 21.0 14.1 0.026
Advanced IS 21.7 23.6 19.3 0.194
Severe IS 37.9 36.4 39.6 0.419
Baseline VL (copies/mL), median (IQR) 270 000 (49 182 - 
1 000 000)
230 000 (32 000 - 
830 000)
326 969 (87 841 - 
1 554 457)
0.0004
Baseline VL log (log10 copies/mL), median (IQR) 5.4 (4.7 - 6.0) 5.4 (4.4 - 6.0) 5.5 (4.8 - 6.0) 0.0005
TB at ART initiation (%) 20.5 16.9 25.3 0.013   
PHC = primary healthcare; ART = antiretroviral therapy; IQR = interquartile range; IS = immunosuppression; VL = viral load; TB = tuberculosis.
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Fig. 2. PHC cohort ART initiation by year and site. (PHC = primary healthcare)
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including >6 years of available data for some 
children and a total of 1 206 observed child-
years. Sustained high levels of VL suppression 
were achieved at each time point (Fig. 3), 
with >80% of the cohort suppressed from the 
12-month visit. At the last VL measurement 
available during the study period, 85% of the 
longitudinal cohort was suppressed. 
Kaplan-Meier survival analysis revealed a sta-
tis tically significant difference in median time 
to VL suppression by ART initiation site: ART-
naive patients whose care was initiated in PHC 
had a median time to suppression of 29 weeks, 
while those down-referred required 44 weeks 
(p<0.0001). Stratification by sex, age, baseline 
WHO immune categorisation, modified SA 
WHO clinical stage and TB co-infection were 
not found to influence time to VL suppression.
Sixty patients (13.9% of the group with 
longitudinal data; 60/431) met the criteria for 
clinically significant VF, with an incidence of 
5.4 cases per 100 child-years. Multiple logistic 
regression modelling revealed that patients 
who started ART in the PHC system were 66% 
(95% confidence interval (CI) 31 - 84) less 
likely to develop VF than patients who were 
down-referred after ART initiation in hospital. 
Additionally, for every one log increase in 
baseline VL, the odds of developing VF 
doubled (95% CI 1.3 - 3.2). Age, history of TB 
disease, protease inhibitor-based ART regimen 
with TB treatment, and baseline immune 
category were not found to be predictive of 
VF within the model; baseline WHO clinical 
classification, however, was so significantly 
predictive that the variable was restricted from 
the model because of colinearity.
Immunological outcomes
Over 80% of the longitudinal cohort main-
tained a CD4+ percentage above baseline at 
each sequential monitoring period; a peak 
prevalence of 96% was achieved at 36 months 
of ART (Fig. 3). The average percentage 
improvement over baseline CD4+ percentage 
steadily rose from a median of 8.7% (IQR 2.3 - 
13.8) at 6 months to a mean of 17.4% (95% 
CI 15.5 - 19.2) at 36 months. Additionally, 
the largest proportion of those with >10% 
improvement in CD4+ percentage above 
baseline was achieved at 36 months. Although 
CD4+ percentage gains drop off after 3 years 
of therapy, lower age-related norms over time 
are the most likely explanation for this finding 
rather than poor response to therapy (given 
rising VL suppression rates).
Thirteen children (2% of the cohort; 1 per 
100 child-years) had evidence of immunological 
failure (IF) after at least 24 weeks of adherent 
ART treatment. Delayed immune reconstitution 
occurred in five IF children (38.5%); in this 
subgroup, CD4+ counts were recovered in 80% 
by 12 months and in all children by 18 months 
of ART. An additional five children (38.5%) 
experienced transient IF despite concurrent 
VL suppression. Although IF resolved by the 
subsequent interval evaluation, it should be 
noted that 40% were undergoing concurrent 
TB treatment. It is therefore possible that 
intercurrent illnesses, TB or otherwise, may 
have contributed to IF. The remaining three 
children with IF (23%) had persistent failure 
despite ongoing VL suppression. One persistent 
IF case experienced immune reconstitution 
after changing the protease inhibitor in her 
ART regimen from ritonavir to lopinavir/
ritonavir.
Mortality 
Documented mortality among the PHC cohort 
was 2.2%, with a maximal mortality estimate 
(documented deaths and LTFU cases) of 6.2%. 
A disproportionate number of children were 
LTFU in the PHC-initiated group (p=0.028); 
given the predominance of new ART initiates 
in this cohort, this finding was of concern for 
undocumented early death after starting ART 
(Fig. 4). Indeed, the incidence of maximal 
mortality was significantly higher (p<0.0001) 
among those who received care for <6 months 
in the PHC system (183 v. 45 deaths per 10 000 
child-years). 
A skewed temporal distribution of 
documented deaths was noted, with 
near-equal numbers experiencing early 
(<3 months) and late (7 - 30 months) 
mortality. Early deaths occurred in infants 
<6 months of age, and young children (11 - 
15 months old) with severe immunological 
suppression (CD4+ percentage 3 - 8.2%). 
Over half of the early mortality group (57%) 
died within the first 9 days of ART therapy. 
Of those with early mortality, 43% were 
receiving dual therapy for HIV and TB, 
VL suppression
CD4+ percentage > baseline
CD4+ improvement >10%
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Fig. 3. Virological and immunological outcomes over 5 years of ART. (ART = antiretroviral therapy; 
VL = viral load.)
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Fig. 4. Maximal mortality after ART initiation. (ART = antiretroviral therapy; LTFU = lost to follow-up.) 
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with TB treatment initiated from 1 week to 3 months before ART 
initiation. 
No difference in maximal mortality between ART initiation sites was 
noted once children had been on ART in the PHC clinics for at least 
6 months (p=0.09). Of note, early mortality data for down-referred 
patients were not available as a result of the nature of the study design. 
Four children who died were not eligible for inclusion in this analysis as 
they died before starting ART within the PHC network.
Outcomes among children down-referred 
from tertiary hospitals
After a median of 2 years (IQR 13.6 - 34 months) on ART, 153 children 
were down-referred from tertiary care to PHC. Of these children, 80% 
had a suppressed VL at the time of down-referral, and 96% of these 
patients remained suppressed at the last measured study evaluation. 
Of the 26 patients transferred with subtherapeutic response to ART, 
77% achieved virological suppression after 6 months of support 
and treatment within the PHC system. Three-quarters of the newly 
suppressed individuals met our criteria for VF at the time of transfer, 
yet only one-third of these children required medication change 
to second-line therapy to achieve successful suppression. Of the 
remaining 6 patients (23%) with ongoing VF: 2 were changed to 3TC 
monotherapy (as a holding strategy); 1 was started on second-line 
therapy immediately prior to the end of the study period (so response 
to the intervention could not be assessed); 2 were transferred to the 
adult ART programme within the same clinic; and only 1 patient 
required referral back to the tertiary care centre. One down-referred 
child died within 3 months of transfer from a tertiary care site (0.6%). 
Discussion
Cohort characteristics reveal that ART initiation site strongly correlates 
with WHO clinical severity; this finding suggests appropriate triage of 
children with advanced HIV disease to higher levels of care. Absolute 
numbers of children initiated on ART within the PHC network suggest 
successful ART roll-out strategies for paediatric patients in the Cape 
Town region. Children receiving ongoing treatment within the PHC 
network demonstrated sustained indices of effective HIV management 
(high VL suppression rates, rapid immune reconstitution, low mortality 
rates) which are comparable with, if not better than, those in previously 
published studies of similar cohorts. [17,25- 29] Overall mortality in the 
cohort was low. Children who died exhibited the following high-risk 
characteristics: dual HIV/TB disease; young age (<6 months); recent ART 
initiation (<3 months on ART); and severe immunological suppression 
in infants <15 months of age. Similar trends in mortality have been noted 
in numerous studies,[18,28,30,31] providing further evidence of a focused 
time period among high-risk patients who may be ideal for a targeted 
intervention. Intensified surveillance of this population would ideally 
result in expedited referral to higher levels of care and decreased mortality.
Although infants and young children are at higher risk for early 
mortality after ART initiation, evidence indicates that intervention 
before 12 weeks of age reduces this risk by 76%.[24] There was 
early adoption of Children with HIV Early Antiretroviral Therapy 
(CHER)-trial recommendations regarding early ART initiation (TBH 
was a CHER trial site), with a disproportionate number of non-
immunosuppressed infants starting ART in tertiary care. Although data 
to support asymptomatic infant ART initiation were first presented in 
mid-2007 at the International AIDS Conference on HIV Pathogenesis, 
Treatment and Prevention, recommendations were more widely 
disseminated through journal and WHO publications towards the end 
of the study period in 2008.[24,32] Although there is evidence of early 
adoption of infant roll-out in tertiary facilities, the temporal nature of 
this study in respect of rapidly changing practice guidelines did not 
allow for true compliance evaluation. An updated analysis of interval 
ART initiation data by site would be required to provide an accurate 
assessment of infant ART roll-out and compliance with current 
recommendations. 
Data from the PHC network are unique in that they arise from an 
exclusively paediatric cohort with down-referral longitudinal data. Near-
perfect rates of sustained VL suppression after tertiary-to-PHC down-
referral are demonstrated among stable patients. Optimistic outcomes 
among predominantly adult down-referred patients are congruent with 
our findings; however, these studies probably suffer from selection 
bias (those offered down-referral were preselected for success).[20,21] 
Unlike these studies, 1 out of every 5 down-referred children had an 
unsuppressed VL at the time of transfer. Among the unsuppressed, 
many had VF, with clinicians noting adherence issues in most. Although 
down-referred children had more cumulative ART exposure with 
associated risk for resistance development, a high proportion achieved 
viral suppression after transfer to PHC without ART regimen change. 
Successful suppression on first-line therapy for those previously failing 
indicates improved adherence, likely to be secondary to decreased 
barriers to community-based care. PHC physicians demonstrated 
expertise in effectively managing those requiring second-line therapy 
with rare referral back to tertiary care centres and low documented 
mortality rates. Substantial improvement in VL suppression rates among 
this subgroup was observed with respect to whether a focus on adherence 
or a change to second-line therapy was prescribed, thereby validating the 
efficacy of this model of care for all-comers.
Conclusion
Although the majority of children were severely ill at ART initiation, 
increasing numbers of less acutely unwell children initiated ART in 
PHC. Our data suggested that intensified surveillance of children 
<15 months of age for the first 3 months of ART may improve 
mortality statistics. Reproducibly well-defined, high-risk patient 
characteristics restricted to a discrete high-risk period yield a clear 
target for programmatic intervention. Long-term ART management 
within PHC clinics by paediatric clinicians yields successful outcomes. 
Down-referral of tertiary-centre-enrolled patients with VF, probably 
adherence related, may be a first-line ART-sparing strategy. 
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